Barclays Maintains Overweight on Eli Lilly, Lowers Price Target to $975
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Eli Lilly (NYSE:LLY) but lowers the price target from $1025 to $975.
October 31, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Eli Lilly but lowers the price target from $1025 to $975.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100